Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival

被引:14
|
作者
Einarsdottir, K. [2 ]
Darabi, H. [1 ]
Czene, K. [1 ]
Li, Y. [3 ]
Low, Y. L. [4 ]
Li, Y. Q. [3 ]
Bonnard, C. [3 ]
Wedren, S. [5 ]
Liu, E. T. [6 ]
Hall, P. [1 ]
Liu, J. [3 ]
Humphreys, K. [1 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden
[2] Univ Western Australia, Sch Populat Hlth, Ctr Hlth Serv Res, Perth, WA 6009, Australia
[3] Genome Inst Singapore, Singapore 138672, Singapore
[4] Brenner Ctr Mol Med, Singapore Inst Clin Sci, Singapore 117609, Singapore
[5] Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden
[6] Genome Inst Singapore, Singapore 138672, Singapore
基金
瑞典研究理事会;
关键词
ESR1; EGF; polymorphism; endometrial cancer; survival; EPIDERMAL-GROWTH-FACTOR; ESTROGEN-RECEPTOR-ALPHA; FUNCTIONAL POLYMORPHISM; SIGNALING PATHWAYS; GASTRIC-CANCER; GENOTYPE DATA; TAGGING SNPS; ASSOCIATION; BREAST; HAPLOTYPES;
D O I
10.1038/sj.bjc.6604984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated common genetic variation in the entire ESR1 and EGF genes in relation to endometrial cancer risk, myometrial invasion and endometrial cancer survival. We genotyped a dense set of single-nucleotide polymorphisms ( SNPs) in both genes and selected haplotype tagging SNPs (tagSNPs). The tagSNPs were genotyped in 713 Swedish endometrial cancer cases and 1567 population controls and the results incorporated into logistic regression and Cox proportional hazards models. We found five adjacent tagSNPs covering a region of 15 kb at the 5' end of ESR1 that decreased the endometrial cancer risk. The ESR1 variants did not, however, seem to affect myometrial invasion or endometrial cancer survival. For the EGF gene, no association emerged between common genetic variants and endometrial cancer risk or myometrial invasion, but we found a five-tagSNP region that covered 51 kb at the 5' end of the gene where all five tagSNPs seemed to decrease the risk of dying from endometrial cancer. One of the five tagSNPs in this region was in strong linkage disequilibrium (LD) with the untranslated A61G (rs4444903) EGF variant, earlier shown to be associated with risk for other forms of cancer.
引用
收藏
页码:1358 / 1364
页数:7
相关论文
共 50 条
  • [31] Genetic polymorphisms of ESR1 and ESR2 that may influence estrogen activity and the risk of hypospadias
    Ban, Susumu
    Sata, Fumihiro
    Kurahashi, Norie
    Kasai, Setsuko
    Moriya, Kimihiko
    Kakizaki, Hidehiro
    Nonomura, Katsuya
    Kishi, Reiko
    HUMAN REPRODUCTION, 2008, 23 (06) : 1466 - 1471
  • [32] Characterization of ESR1 mutations in endometrial and ovarian cancers.
    Gaillard, Stephanie
    Bayable, Asnakech
    Deshmukh, Sachin Kumar
    Nayar, Utthara
    Xiu, Joanne
    Ingram, Lishann
    Hubbard, Gretchen
    Sledge, George W.
    Herzog, Thomas J., Jr.
    Thaker, Premal H.
    Wu, Sharon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] ESR1 Gene Amplification in Endometrial Carcinomas: A Clinicopathological Analysis
    Rahman, Mohammed Tanjimur
    Nakayama, Kentaro
    Rahman, Munmun
    Ishikawa, Masako
    Katagiri, Hiroshi
    Katagiri, Atsuko
    Ishibashi, Tomoka
    Sato, Emi
    Iida, Kouji
    Ishikawa, Noriyuki
    Nakayama, Naomi
    Miyazaki, Kohji
    ANTICANCER RESEARCH, 2013, 33 (09) : 3775 - 3781
  • [34] Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms
    McIntyre, Matthew H.
    Kantoff, Philip W.
    Stampfer, Meir J.
    Mucci, Lorelei A.
    Parslow, Diane
    Li, Haojie
    Gaziano, J. Michael
    Abe, Miyako
    Ma, Jing
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) : 2233 - 2236
  • [35] ABERRANT METHYLATION OF ESR1 IN BLOOD AND ASSOCIATION WITH ESR1 NEGATIVE IN TUMOR OF BREAST CANCER PATIENTS
    Martinez-Galan, J.
    Torres-Torres, B.
    del Moral, R.
    Nunez, M. I.
    Valdivia, J.
    Luque, R.
    Penalver, J.
    Rios, S.
    De Almodovar, M. Ruiz
    Delgado, J. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 52 - 52
  • [36] De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
    Morel, Adeline
    Masliah-Planchon, Julien
    Bataillon, Guillaume
    Becette, Veronique
    Morel, Claire
    Antonio, Samantha
    Girard, Elodie
    Bieche, Ivan
    Le Tourneau, Christophe
    Kamal, Maud
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 3
  • [37] On the evidence for ESR1 amplification in breast cancer
    Frederik Holst
    Cathy B. Moelans
    Martin Filipits
    Christian F. Singer
    Ronald Simon
    Paul J. van Diest
    Nature Reviews Cancer, 2012, 12 : 149 - 149
  • [38] Variants on ESR1 and their Association with Prostate Cancer Risk: A Meta-analysis
    Ding, Xiang
    Cui, Feng-Mei
    Xu, Song-Tao
    Pu, Jin-Xian
    Huang, Yu-Hua
    Zhang, Jiang-Lei
    Wei, Xue-Dong
    Hou, Jian-Quan
    Yan, Chun-Yin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3931 - 3936
  • [39] On the evidence for ESR1 amplification in breast cancer
    Holst, Frederik
    Moelans, Cathy B.
    Filipits, Martin
    Singer, Christian F.
    Simon, Ronald
    van Diest, Paul J.
    NATURE REVIEWS CANCER, 2012, 12 (02) : 149 - 149
  • [40] The search for ESR1 mutations in breast cancer
    Oesterreich, Steffi
    Davidson, Nancy E.
    NATURE GENETICS, 2013, 45 (12) : 1415 - 1416